Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hen egg-white lysozyme is a small, stable enzyme (129 amino acids) that hydrolyzes β(1→4) glycosidic bonds between N-acetylmuramic acid and N-acetylglucosamine in bacterial cell walls, thereby conferring antibacterial activity. The enzyme is highly abundant in bird egg whites and secretions like tears and saliva, serving an important defensive role in innate immunity. The aggregation interface refers to structural regions of lysozyme that interact during protein aggregation under destabilizing conditions—such as elevated temperature or altered pH—leading to the formation of amyloid-like fibrils. Aggregation studies are primarily biophysical and relate to understanding protein misfolding, not to drug targeting. If your intent is to catalog molecular targets for drug development or clinical applications, revert to "Hen egg-white lysozyme" (HEWL) rather than the aggregation interface, as only the enzyme has established classification, function, and aliases. The aggregation interface is a laboratory research concept and not a canonical target.
Not applicable for aggregation interface. Lysozyme enzyme itself cleaves β(1→4) glycosidic bonds in peptidoglycans
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hen egg-white lysozyme aggregation interface.